AIM ImmunoTech Inc. (AIM)
| Market Cap | 4.21M +91.5% |
| Revenue (ttm) | 88,000 -48.2% |
| Net Income | -13.96M |
| EPS | -8.62 |
| Shares Out | 8.15M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 98,136 |
| Open | 0.5181 |
| Previous Close | 0.5200 |
| Day's Range | 0.5009 - 0.5282 |
| 52-Week Range | 0.4750 - 20.3300 |
| Beta | 1.36 |
| Analysts | Strong Buy |
| Price Target | 10.00 (+1,833.49%) |
| Earnings Date | Mar 27, 2026 |
About AIM
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also d... [Read more]
Financial Performance
In 2025, AIM ImmunoTech's revenue was $88,000, a decrease of -48.24% compared to the previous year's $170,000. Losses were -$13.96 million, -19.41% less than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for AIM stock is "Strong Buy" and the 12-month stock price target is $10.0.
News
AIM ImmunoTech Transcript: Virtual Investor Closing Bell
Ampligen’s focus on late-stage pancreatic cancer is driven by strong clinical data, significant unmet need, and robust market opportunity. The ongoing phase II DURIPANC study shows positive interim re...
AIM ImmunoTech Provides Routine Update on Annual Filings
OCALA, Fla., April 13, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today advised that its audited consolidated financial statements for the fiscal year e...
AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors
AIM also intends to pursue Japanese Orphan Drug Designation for Ampligen in treatment of pancreatic cancer AIM also intends to pursue Japanese Orphan Drug Designation for Ampligen in treatment of panc...
AIM ImmunoTech Announces Closing of its Rights Offering
OCALA, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and developmen...
AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer
OCALA, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced an agreement with the PPD™ clinical research business of Thermo Fisher...
AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering
OCALA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development...
AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer
OCALA, Fla., Feb. 23, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced milestones in the expected timeline for the ongoing Phase 2 clinical st...
AIM ImmunoTech Transcript: Virtual Investor Closing Bell
Ampligen is advancing as a promising therapy for pancreatic cancer, showing strong safety, improved survival, and quality of life in clinical trials. Orphan drug status and robust data support a pivot...
CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering
This press release is issued solely to correct a date from an AIM press release dated February 11, 2026. The Subscription Rights will expire if they are not exercised by 5:00 p.m., Eastern Time, on Fe...
AIM ImmunoTech Transcript: Corporate Connect Webinar Series
Ampligen is advancing as a novel therapy for late-stage pancreatic cancer, showing significant survival and quality of life benefits in early studies. Ongoing phase II trials with AstraZeneca's Imfinz...
AIM ImmunoTech Announces Commencement of Rights Offering
OCALA, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development...
AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
Live video webcast on Wednesday, February 11 th at 1:40 PM EST
AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
Year-end report discusses combination therapy's Mechanism of Action activating both innate and adaptive immune responses Year-end report discusses combination therapy's Mechanism of Action activating ...
AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering
OCALA, Fla., Jan. 23, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development...
AIM ImmunoTech Transcript: AGM 2025
The meeting covered board elections, auditor ratification, and executive compensation proposals, with voting conducted virtually and final results to be filed later. No questions were submitted by sto...
AIM ImmunoTech Transcript: Virtual Investor Closing Bell Series
Ampligen is advancing as a platform immuno-oncology drug, with a strategic focus on pancreatic cancer due to strong clinical data and significant unmet need. Ongoing collaborations with AstraZeneca an...
AIM ImmunoTech to Participate in Live ‘Fireside' Chat on Virtual Investor Closing Bell Series
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, December 4th at 4:00 PM ET Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on...
AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program
OCALA, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today provided a business update and reported its financial results for the third quar...
AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen's Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer
OCALA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today detailed a recent abstract containing data from the completed Phase 2 advanced re...
AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
OCALA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data from the completed Phase 2 cisplatin-resistant advanced recur...
AIM ImmunoTech to Attend the 2025 Maxim Growth Summit
OCALA, Fla., Oct. 20, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced it will participate at the 2025 Maxim Growth Summit, taking place Octo...
AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors
Patent supports AIM's strategy to expand international market protection, providing opportunities for licensing, collaborations, and long-term revenue growth
AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland
Latest progress from lead program Ampligen for the treatment of pancreatic cancer highlighted at the International 5 th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2...
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Tom Equels, CEO of AIM ImmunoTech provides a corporate update and reiterates focus on driving Ampligen forward in pancreatic cancer Tom Equels, CEO of AIM ImmunoTech provides a corporate update and re...
AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Continued progress across pipeline programs with focus on pancreatic cancer Mid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca's Imfinzi® (durvalumab) for the treatment of pan...